Next Score View the next score

    Mass. Movers

    Cambridge’s Idenix up on pipeline update

    Cambridge’s Idenix Pharmaceuticals Inc. reported third-quarter revenue of less than $0.1 million, compared to $32.3 million a year ago. The company said it lost $34 million, compared to a profit of $4.3 million, last year. But investors showed optimism after Idenix gave an update on its product pipeline. It said that its hepatitis C treatment has received approval to enter clinical trials in Canada and Belgium, and that all patients had completed enrollment in the first phase of its midstage trial involving samatasvir, its NS5A inhibitor.